Ad
Wednesday, 1 August 2018
Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources
HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment